Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | Dexamethasone + Ribociclib |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Dexamethasone | Adexone | Desametasone | ||
Ribociclib | Kisqali | LEE011 | CDK4/6 Inhibitor 10 | Kisqali (ribociclib) is a dual CDK4/6 inhibitor, which may induce cell cycle arrest and reduce proliferation in cancer cells (PMID: 24045179). Kisqali (ribociclib) is FDA-approved in combination with an aromatase inhibitor in women with hormone receptor-positive, ERBB2 (HER2)-negative breast cancer, and in combination with Faslodex (fulvestrant) in postmenopausal women with hormone receptor-positive, ERBB2 (HER2)-negative breast cancer (FDA.gov). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
NOTCH1 mut RB1 wild-type | T-cell adult acute lymphocytic leukemia | sensitive | Dexamethasone + Ribociclib | Preclinical - Cell line xenograft | Actionable | In a preclinical study, the combination of Kisqali (ribociclib) and Adexone (dexamethasone) treatment in a T-cell acute lymphoblastic leukemia cell line harboring wild-type RB1 and a NOTCH1 mutation resulted in decreased cell viability and reduced phosphorylation of Rb1 in culture, and a greater survival benefit in xenograft models when compared to Kisqali (ribociclib) alone (PMID: 28151717). | 28151717 |
NOTCH1 wild-type RB1 wild-type | T-cell adult acute lymphocytic leukemia | conflicting | Dexamethasone + Ribociclib | Preclinical - Cell line xenograft | Actionable | In a preclinical study, the combination of Kisqali (ribociclib) and Adexone (dexamethasone) in a T-cell acute lymphoblastic leukemia cell line harboring wild-type RB1 and NOTCH1 resulted in decreased cell viability and reduced phosphorylation of Rb1 in culture, however, survival did not differ between xenograft models treated with the combination or Kisqali (ribociclib) alone (PMID: 28151717). | 28151717 |
NOTCH1 act mut | T-cell adult acute lymphocytic leukemia | predicted - sensitive | Dexamethasone + Ribociclib | Preclinical - Pdx | Actionable | In a preclinical study, the combination of Kisqali (ribociclib) and Adexone (dexamethasone) resulted in reduced leukemia burden and a greater survival benefit in a NOTCH1 activated T-cell acute lymphoblastic leukemia patient derived xenograft (PDX) model when compared to control or either agent alone (PMID: 28151717). | 28151717 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03740334 | Phase I | Dexamethasone + Ribociclib Dexamethasone + Everolimus + Ribociclib | Ribociclib in Combination With Everolimus and Dexamethasone in Relapsed ALL | Recruiting | USA | 0 |